Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine

We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside antimetabolite 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106). The cytotoxicity of TAS-106 in vitro against human tumors was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of cancer research (Gann) 2001-03, Vol.92 (3), p.343-351
Hauptverfasser:	SHIMAMOTO, Yuji, FUJIOKA, Akio, KAZUNO, Hiromi, MURAKAMI, Yuko, OHSHIMO, Hideyuki, KATO, Toshiyuki, MATSUDA, Akira, SASAKI, Takuma, FUKUSHIMA, Masakazu
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antimetabolites, Antineoplastic - pharmacokinetics Antimetabolites, Antineoplastic - therapeutic use Antimetabolites, Antineoplastic - toxicity Antineoplastic agents Biological and medical sciences Breast Neoplasms Cell Survival - drug effects Chemotherapy Colonic Neoplasms Cytidine - analogs & derivatives Cytidine - pharmacokinetics Cytidine - therapeutic use Cytidine - toxicity Female Humans Lung Neoplasms - drug therapy Male Medical sciences Pancreatic Neoplasms Pharmacology. Drug treatments Rats Rats, Inbred F344 Rats, Nude Stomach Neoplasms - drug therapy Tissue Distribution Transplantation, Heterologous Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!